As the market for specialty and generic products continues to become more competitive and pricing pressures increase, the 505(b)(2) pathway may allow companies more options to diversify their portfolios.
Mohit Jain
Advertisement
Articles by Mohit Jain
Advertisement
Latest Updated Articles
505(b)(2): A Pathway to Competitiveness Through Innovation for Specialty and Generic CompaniesPublished: December 4th 2019 | Updated:
Advertisement
Advertisement
Trending on PharmExec
1
Your Phase III Clinical Protocol Is Your Initial Product Launch
2
Pharmaceutical Executive Daily: Public Citizen Sues The Trump Administration Over Undisclosed Drug Price Agreements
3
AstraZeneca Enters $4.7 Billion Collaboration Agreement with CSPC Pharmaceuticals
4
Taking Advantage of ‘Hidden Gem’ Talent Hubs
5